X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Lupuzor (Forigerimod) have unique mechanism of action involves modulating the activation of auto-reactive T-cells, which is investigated for treatment of systemic lupus erythematosus.
Lead Product(s): Forigerimod
Therapeutic Area: Immunology Product Name: Lupuzor
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
As part of the Type ‘A’ Meeting, Avion has asked the FDA for guidance on the Key aspects of the study design, clinical end points and approval process for Lupuzor™; and Consideration by the FDA for a conditional approval of Lupuzor™, whilst the Phase 3 trial is underway.
Lead Product(s): IPP-201101
Therapeutic Area: Immunology Product Name: Lupuzor
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2020
Details:
Investigation of the application of the Ureka peptide technologies within the Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies.
Lead Product(s): IPP-201101
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol.
Lead Product(s): Rigerimod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Avion Pharmaceuticals
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
